Trial Enrollment Completed for Investigational Therapy of Exocrine Pancreatic Insufficiency First Wave BioPharma, Inc. (NASDAQ: FWBI), a clinical-stage biopharmaceutical company
March S&P 500 futures (ESH23) are trending down -0.33% this morning after three major U.S. benchmark indices shook off early losses and closed higher on Friday as investors assessed the start of the U.S....
First Wave's (FWBI) stock gains as FDA reviews its IND amendment for the planned phase II study of an enhanced enteric microgranule delivery formulation of adrulipase.
/PRNewswire/ -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa"), a clinical- stage specialty biopharmaceutical company developing first-in-class drugs...
After losing some value lately, a hammer chart pattern has been formed for First Wave BioPharma, Inc. (FWBI), indicating that the stock has found support. This, combined with an upward trend in earnings...
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage...
BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a...
Committee members include globally renowned experts in gastrointestinal diseases, including ulcerative colitis and Crohn’s disease...
BOCA RATON, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a...
BOCA RATON, Fla., March 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a...